Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial - Concepedia

Concepedia

Publication | Closed Access

Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial

306

Citations

39

References

2003

Year

Edward M. Messing, Judith Manola, George Wilding, Kathleen J. Propert, Jonathan Fleischmann, E. David Crawford, J. Edson Pontes, Richard G. Hahn, Donald L. Trump

Journal of Clinical Oncology

Abstract

Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients.

References

	Year	Citations

Page 1